CRISPR/Cas9 technology generated a methionine to threonine substitution at amino acid 228 (p.M228T). Three silent base pair changes were also introduced to create an Hgal restriction site for genotyping. p.M228T is a missense variant identified in the actin-binding domain in patients with hypertrophic cardiomyopathy. (J:334092)